खोज परिणाम - Klaus M. Breiner

  • प्रदर्शित 1 - 4 परिणाम 4
परिणाम को परिष्कृत करें
  1. 1
    Carboxypeptidase D (gp180), a Golgi-Resident Protein, Functions in the Attachment and Entry of Avian Hepatitis B Viruses

    Carboxypeptidase D (gp180), a Golgi-Resident Protein, Functions in the Attachment and Entry of Avian Hepatitis B Viruses द्वारा Klaus M. Breiner, Stephan Urban, Heinz Schaller

    प्रकाशित 1998
    पूर्ण पाठ प्राप्त करें पूर्ण पाठ प्राप्त करें
    Artigo
    सूची में सहेजें
    में बचाया:
  2. 2
    Endothelial cell-mediated uptake of a hepatitis B virus: A new concept of liver targeting of hepatotropic microorganisms

    Endothelial cell-mediated uptake of a hepatitis B virus: A new concept of liver targeting of hepatotropic microorganisms द्वारा Klaus M. Breiner, Heinz Schaller, Percy A. Knolle

    प्रकाशित 2001
    पूर्ण पाठ प्राप्त करें पूर्ण पाठ प्राप्त करें
    Artigo
    सूची में सहेजें
    में बचाया:
  3. 3
    A phase 1 trial extension to assess immunologic efficacy and safety of prime-boost vaccination with VXM01, an oral T cell vaccine against VEGFR2, in patients with advanced pancreatic cancer

    A phase 1 trial extension to assess immunologic efficacy and safety of prime-boost vaccination with VXM01, an oral T cell vaccine against VEGFR2, in patients with advanced pancreat... द्वारा Friedrich H. Schmitz-Winnenthal, Nicolas Hohmann, Thomas Schmidt, Lilli Podola, Tobias Friedrich, Heinz Lubenau, Marco Springer, Sébastien Wieckowski, Klaus M. Breiner, Gerd Mikus, Markus W. Büchler, Anne-Valérie Keller, Ruhan Koc, Christoph Springfeld, Phillip Knebel, Mariana Bucur, Lars Grenacher, Walter E. Haefeli, Philipp Beckhove

    प्रकाशित 2017
    पूर्ण पाठ प्राप्त करें पूर्ण पाठ प्राप्त करें
    Artigo
    सूची में सहेजें
    में बचाया:
  4. 4
    Anti-angiogenic activity of VXM01, an oral T-cell vaccine against VEGF receptor 2, in patients with advanced pancreatic cancer: A randomized, placebo-controlled, phase 1 trial

    Anti-angiogenic activity of VXM01, an oral T-cell vaccine against VEGF receptor 2, in patients with advanced pancreatic cancer: A randomized, placebo-controlled, phase 1 trial द्वारा Friedrich H. Schmitz-Winnenthal, Nicolas Hohmann, Andreas G. Niethammer, Tobias Friedrich, Heinz Lubenau, Marco Springer, Klaus M. Breiner, Gerd Mikus, Jürgen Weitz, Alexis Ulrich, Markus W. Buechler, Frank Pianka, Ulla Klaiber, Markus K. Diener, Christine Leowardi, Simon Schimmack, Leila Sisic, Anne-Valérie Keller, Ruhan Koc, Christoph Springfeld, Philipp Knebel, Thomas Schmidt, Yingzi Ge, Mariana Bucur, Slava Stamova, Lilli Podola, Walter E. Haefeli, Lars Grenacher, Philipp Beckhove

    प्रकाशित 2015
    पूर्ण पाठ प्राप्त करें पूर्ण पाठ प्राप्त करें
    Artigo
    सूची में सहेजें
    में बचाया:

खोज साधन: